Expand ARWR Menu
ARWR MENU

ARWR Latest Press Releases

-- March 10, 2025 --

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy Business Wire 7:30 AM

-- March 6, 2025 --

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases Business Wire 8:45 AM

-- February 28, 2025 --

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) Business Wire 9:00 AM

-- February 25, 2025 --

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity Business Wire 7:30 AM

-- February 10, 2025 --

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results Business Wire 4:01 PM
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics Business Wire 8:30 AM

-- January 22, 2025 --

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 PRNewswire 5:54 PM
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results Business Wire 4:00 PM

-- January 17, 2025 --

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome Business Wire 4:30 PM

-- December 23, 2024 --

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Business Wire 7:30 AM

-- December 19, 2024 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:59 PM

-- December 3, 2024 --

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity Business Wire 7:30 AM

-- December 2, 2024 --

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences Business Wire 7:30 AM

-- November 26, 2024 --

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results Business Wire 4:00 PM
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs Business Wire 7:00 AM
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs Business Wire 7:00 AM

-- November 18, 2024 --

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome Business Wire 7:31 AM
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran Business Wire 7:30 AM

-- November 5, 2024 --

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results Business Wire 7:30 AM

-- November 4, 2024 --

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences Business Wire 7:30 AM

-- November 1, 2024 --

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome Business Wire 7:30 AM

-- October 14, 2024 --

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Business Wire 4:30 PM